Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dificid

- PMLiVE

ICER extends evaluation of Biogen’s aducanumab after FDA delay

FDA delayed its decision on potential Alzheimer's therapy to 7 June

- PMLiVE

FDA grants emergency use for Lilly’s COVID-19 antibody drug combination

Bamlanivimab plus etesevimab shown to reduce risk of death in high-risk COVID-19 patients

- PMLiVE

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

Post-marketing study shows increased risk of serious heart-related problems and cancer with Xeljanz

EU flag

EU orders another 300 million doses of Pfizer/BioNTech’s COVID-19 vaccine

Pfizer/BioNTech's has an existing agreement with the EU for an initial 300 million doses

- PMLiVE

FDA schedules meeting on 26 February to review J&J’s one-dose COVID-19 vaccine

Vaccine candidate demonstrated an overall efficacy of 66% in phase 3

- PMLiVE

Merck’s CEO Kenneth Frazier to retire after ten years in the role

Frazier is handing the reins over to current Merck CFO Robert Davis

- PMLiVE

Rolling reviews of Novavax’s COVID-19 vaccine begin across the globe

And the FDA is planning rapid reviews for COVID-19 vaccine boosters

- PMLiVE

Pfizer aims for $15bn in 2021 COVID-19 vaccine sales

Current estimate is based on already agreed contracts

- PMLiVE

UK launches world-first COVID-19 study evaluating a mixed-vaccine regimen

Participants could receive AZ/Oxford University's vaccine for their first dose and Pfizer/BioNTech's vaccine for their second

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

Can Science Save Us?

Dr. Mark Poznansky, Founder/Blogger at Saved By Science explores the importance of improving health literacy among the general population, along with the scientific and technological innovations that he believes could help save...

Impetus Digital

- PMLiVE

South Africa COVID-19 variant ‘unlikely’ to reduce efficacy of Pfizer/BioNTech jab

Lab study tested blood samples of vaccinated individuals against key virus mutations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links